Why the FDA’s Plan to Embrace Human-Specific Research is Cause for Optimism
By Ross Dobie. In this article, I digest the recent announcement and outline the key reasons for my optimism regarding the proposed roadmap. My thoughts / insights are marked in italics.

Like
Be the first to like this
The tide is turning as the U.S. Food and Drug Administration (FDA) gives the strongest signal to date that the future of preclinical safety assessment in the U.S. will rely increasingly on human-specific research as animal testing is phased out. Their mission is clear: ‘to improve drug safety and accelerate the evaluation process, while reducing animal experimentation, lowering research and development (R&D) costs, and ultimately, drug prices.’
Please sign in or register for FREE
If you are a registered user on WORC.Community, please sign in